MiNK Therapeutics (NASDAQ:INKT) Director Barbara Ryan Sells 1,300 Shares

MiNK Therapeutics, Inc. (NASDAQ:INKT) Director Barbara Ryan sold 1,300 shares of the stock in a transaction on Tuesday, March 10th. The shares were sold at an average price of $15.40, for a total value of $20,020.00. Following the completion of the transaction, the director owned 20,406 shares of the company’s stock, valued at $314,252.40. This trade represents a 5.99% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Barbara Ryan also recently made the following trade(s):

• On Monday, March 9th, Barbara Ryan sold 200 shares of MiNK Therapeutics stock. The stock was sold at an average price of $10.17, for a total value of $2,034.00.
• On Monday, March 2nd, Barbara Ryan sold 100 shares of MiNK Therapeutics stock. The stock was sold at an average price of $10.83, for a total value of $1,083.00.
• On Friday, February 27th, Barbara Ryan sold 400 shares of MiNK Therapeutics stock. The stock was sold at an average price of $10.86, for a total transaction of $4,344.00.

MiNK Therapeutics Stock Down 17.2%

Shares of MiNK Therapeutics stock traded down $2.33 during trading on Wednesday, hitting $11.18. The stock had a trading volume of 385,366 shares, compared to its average volume of 354,533. MiNK Therapeutics, Inc. has a 1 year low of $6.34 and a 1 year high of $76.00. The stock has a 50 day simple moving average of $11.58 and a 200 day simple moving average of $12.77. The company has a market capitalization of $52.43 million, a PE ratio of -3.69 and a beta of 0.35.

MiNK Therapeutics News Summary

Here are the key news stories impacting MiNK Therapeutics this week:

• Positive Sentiment: Announced a strategic collaboration with C‑Further to develop a PRAME‑targeted TCR‑engineered iNKT cell therapy for pediatric cancers and will receive roughly $1.1M in non‑dilutive funding to advance the program — this is the core fundamental catalyst behind recent buying. MiNK Therapeutics Announces Collaboration with C‑Further
• Positive Sentiment: Market reaction: shares surged (reports of up to ~80% intraday moves) on the collaboration news, reflecting strong speculative and momentum buying around the pediatric oncology program. MiNK Therapeutics stock soars 80% on C‑Further collaboration
• Neutral Sentiment: Analyst consensus is an average “Hold,” which tempers upside from fundamentals and may limit conviction among institutional investors ahead of upcoming quarterly reporting. MiNK Therapeutics, Inc. Given Average Recommendation of “Hold” by Analysts
• Negative Sentiment: Short‑term technical/flow pressure: headlines suggest today’s pullback is driven by profit‑taking after the big rally, a common follow‑through after rapid gains that can accelerate selling. Why Is MiNK Therapeutics Stock Trading Lower On Wednesday?
• Negative Sentiment: Short interest rose ~18% in February to 37,106 shares (≈1.0% of float) with an 8.6‑day cover ratio — increased shorting can add downward pressure and volatility if momentum reverses.

Hedge Funds Weigh In On MiNK Therapeutics

An institutional investor recently bought a new position in MiNK Therapeutics stock. DRW Securities LLC acquired a new stake in shares of MiNK Therapeutics, Inc. (NASDAQ:INKT) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 25,677 shares of the company’s stock, valued at approximately $286,000. DRW Securities LLC owned about 0.55% of MiNK Therapeutics at the end of the most recent quarter. 2.87% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen raised shares of MiNK Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, January 19th. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, MiNK Therapeutics presently has an average rating of “Hold” and an average target price of $35.00.

MiNK Therapeutics Company Profile

MiNK Therapeutics, Inc is a clinical-stage biotechnology company developing exosome-based immunotherapies for the treatment of solid tumors. The company’s proprietary platform isolates and engineers naturally occurring extracellular vesicles, or exosomes, to deliver therapeutic payloads—such as mRNA, proteins and modulatory factors—directly into the tumor microenvironment. By leveraging the innate cell‐to‐cell communication properties of exosomes, MiNK aims to reprogram immune cells and overcome immune suppression within solid tumors.

MiNK’s preclinical pipeline features multiple lead candidates designed to repolarize tumor‐associated macrophages and boost T cell–mediated tumor clearance.